рус     /     укр     /     eng


Feminal all products »
Department of sales and marketing
tel. +38 (044) 463-50-77

TB basic science / Clinical trials and TB treatment

P14, 91121 ADJUNCT IMMUNOTHERAPY OF XDR-TB, GA Kutsyna,1 N Nathalia Prihoda,2 O Olga Arjanova,2 V Volodymyr Pylypchuk3 'Lubansk State Medical University, Luhansk, Ukraine; 2Lisichansk TB Dispensary, Lisichansk, Ukraine; 3EkomedLLC, Kiev, Ukraine. Fax: (380) 1234S678 e-mail: kutsyna@list ru

Keywords: immunotherapy; drug-resistant TB; XDR-TB According to the latest study patients with extensively drug-resistant tuberculosis (XDR-TB) had higher mortality rate than patients with MDR-TB [1], Only 29,3% of those with XDR-TB were cured compared to 46 2% of patients with MDR-TB [2] TB therapy success rate in Russian patients with XDR-TB as reported by Keshavjee et al., was 48.3% [3]. Earlier reported cure rates in Europe, USA, Peru and Korea were between 37.5%-67% indicating that XDR-TB poses serious clinical challenge [4­7], We have shown that immune-modulating interventions can significantly improve TB treatment outcomes [8]. We treated twelve XDR-TB individuals, seven of which in addition to standard chemotherapy received Dzherelo (Immunoxel), Svitanok and Lisorm - over-the-counter herbal immunomodulators available in Ukraine (Table 1) All these seven patients improved clinically and radiologically and were discharged after 3.7±0.8 months, with average/median time to mycobacterial clearance 28/25 days. None of five patients on TB drugs alone improved and one had died. These results reveal statistically different treatment outcomes due to immune intervention (Mantel Haenszel odds ratio= 11; P= 0.0009 at 95% CI). Adjunct herbal immunotherapy is safe, shortens treatment duration, and can overcome drug resistance even in patients with extremely poor prognosis. Further studies are needed to confirm our findings.

Read also:

Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator DzhereloClinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patientsImmune approaches in tuberculosis therapy: a brief overviewAdjuvant Immunotherapy of Extensively Drug-Resistant Tuberculosis (XDR-TB) in Ukraine
Rated by PING
© 2010 - Ekomed. All rights reserved.
Sites development
Подбайте про своє здоров'я разом з порталом Спортивні клуби України